He Already Agreed to Pay ₹235. Yesterday He Bought More at ₹232.

What Happened

On 28 August 2026, Ashish Dhawan acquired 38,00,000 equity shares of Religare Enterprises through an open market purchase.

The trade appears on the exchange tape as two blocks, 20,00,000 shares and 18,00,000 shares, both at ₹232.00. Total consideration ₹88,16,00,000, or ₹88.16 crore.

His disclosure under Regulation 29(2) of the SEBI Takeover Regulations confirms it:

Shares Stake Before 1,78,80,852 5.24% After 2,16,80,852 6.35% Acquired 38,00,000 +1.11 points

Total diluted share capital after the acquisition stands at 39,68,19,811 shares. Note that the 5.24% and 6.35% figures are calculated on paid-up capital of roughly 34.13 crore shares, not on the diluted number. Both figures appear in the filing and they measure different bases.

Who he is. Ashish Dhawan founded ChrysCapital in 1999 and built it into one of India’s largest private equity firms, before stepping back from full-time investing to found Ashoka University and the Central Square Foundation. He is not a promoter of Religare, holds no board seat, and has no control over the company’s decisions.

The Number Most People Miss

In 2025, Religare’s board approved a capital raise of ₹1,500 crore through a preferential allotment of 6,38,29,782 convertible warrants at ₹235 each.

The Burman family of Dabur, the company’s promoter group, subscribed to ₹750 crore, exactly half. The remaining ₹750 crore came from a set of named investors including the Hindustan Times Media Group, JM Financial, and Ashish Dhawan.

On 4 June 2026, Dhawan’s warrant conversion went through. 17,00,000 warrants were extinguished at ₹235 per warrant and the corresponding equity shares were issued.

So he had already committed to owning this stock at ₹235.

Yesterday he bought 38 lakh more shares in the open market at ₹232.

Below his own conversion price.

There is a second layer to that number. When the Burman family made its mandatory open offer for Religare in September 2023, seeking up to 9,00,42,541 shares for 26% of the expanded capital, the offer price was also ₹235. That figure has anchored this company’s ownership story for three years, and the stock now trades under it.

This Is Not a New Position

Do not read this as a fresh entry. It is the latest step in a long accumulation.

Disclosures from October 2023 showed Dhawan at 2.32%. He is now at 6.35%. That is nearly three years of steady building.

One important distinction. Part of that increase came from the warrant conversion in June, which is a mechanical event, not a market purchase. Only the 28 August transaction was an open market buy. Anyone presenting the entire move from 2.32% to 6.35% as continuous open market accumulation has not read the filings.

And the promoters have been buying too. Between 18 and 27 March 2026, promoter group entities Shivani Burman and Gyan Enterprises Private Limited acquired 83.33 lakh equity shares, about 2.11% of share capital, through open market purchases. A separate Regulation 31(4) disclosure filed on 7 April 2026 confirmed no encumbrance on the 10,07,75,486 shares held by the promoter group as of 31 March 2026. No pledging.

What He Is Actually Buying

Religare Enterprises, incorporated in 1984, is a holding company. It does not run one business, it owns four.

Business Entity Share of revenue Health insurance Care Health Insurance 74.5% Retail broking Religare Broking 8.5% SME finance Religare Finvest (RFL) Affordable housing finance Religare Housing Development Finance

Its subsidiaries serve over 11 lakh clients from more than 1,275 locations across 400-plus cities.

Three quarters of the revenue is health insurance. That matters, because it means Religare is far more an insurance holding company than a lender, and the insurance arm is the part that is working.

The Quarter, Read Properly

Q1 FY27, reported on 13 August 2026:

Q1 FY26 Q1 FY27 Consolidated revenue ₹1,876.3 Cr ₹2,358.4 Cr, up 26% Profit after tax ₹8.1 Cr Loss of ₹46.9 Cr Net worth ₹2,553.4 Cr ₹3,061.9 Cr, up 20% Cash and equivalents ₹378.3 Cr, up 170%

The headline is a loss. The detail is more mixed than that.

Care Health Insurance grew gross written premium 37% year on year to ₹3,247 crore, and scaled its investment book to ₹11,751 crore. That is the 74.5% of the business, and it is compounding fast.

But the insurance business is still not profitable at the underwriting level. The combined ratio is 102.7%, meaning claims and expenses exceed premiums collected. Management has guided to reaching 100% within roughly two years. Until that happens, growth in premium is growth in a loss-making book.

The SME lending arm, Religare Finvest, has not restarted lending. Management guides to a restart in three to four months, with ₹250 crore committed to housing finance. The company reports CRAR of 120.5% and no external borrowings at the holding level, and completed ₹147 crore of warrant conversion in June.

The Overhang

On 6 August 2026, the Reserve Bank of India declined the proposed demerger. The company has stated that it will engage with the regulator and provide further clarifications.

This is not a small matter. When the RBI cleared the Burman family’s open offer, it did so subject to a condition that the acquirers consolidate the NBFCs across both the Burman and Religare groups, with a concrete plan and timelines supported by board resolutions. The group’s structure has been a live regulatory question since the takeover, and it remains unresolved.

The Risks

1. Q1 FY27 was a consolidated loss of ₹46.9 crore, against a profit of ₹8.1 crore a year earlier, despite 26% revenue growth.

2. The RBI declined the demerger on 6 August 2026. The outcome is unknown and it is a structural question, not an operational one.

3. The insurance combined ratio is 102.7%. The largest business by far still loses money on underwriting.

4. Return on equity is 4.47% over three years. Interest coverage is low.

5. The SME lending business is not operating. A restart has been guided but not delivered.

6. This company carries significant governance history. It has been through a contested takeover, investigations by SEBI and the Ministry of Corporate Affairs, and an ED special court has summoned five individuals in a money laundering matter connected to the prior management era.

7. Dhawan is not a promoter and holds no board seat. He is a large minority shareholder with no control over outcomes.

8. Part of his stake increase was warrant conversion, not buying. Only the 28 August transaction was an open market purchase.

9. The stock is not at a corrected level. It trades near ₹232 against a 52-week high of ₹280 recorded on 25 June 2026, and a 52-week low of ₹196.51 on 9 March 2026.

10. He has been early before, and being early is indistinguishable from being wrong until it isn’t. He committed at ₹235 and the stock is below that today.

This content is for educational purposes only. It is not investment advice, not a recommendation to buy, sell or hold any security, and contains no price target or entry level. All figures are sourced from exchange filings, company disclosures and management commentary as on 29 August 2026. Where sources conflicted, I have used the exchange filing or omitted the figure entirely. Please consult your financial advisor before investing.